Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
Beam Therapeutics (Nasdaq: BEAM) announced it will host a conference call and webcast on November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results. The company will also review abstracts accepted for presentation at the 66th Annual Meeting of the American Society for Hematology (ASH). A live webcast will be available on the company's website, with a replay accessible for 60 days following the presentation.
Beam Therapeutics (Nasdaq: BEAM) ha annunciato che ospiterà una conferenza telefonica e un webcast il 5 novembre 2024 alle 8:30 ET per discutere i risultati finanziari del terzo trimestre 2024. L'azienda esaminerà anche i riassunti accettati per la presentazione al 66° Congresso Annuale della Società Americana di Ematologia (ASH). Un webcast dal vivo sarà disponibile sul sito web dell'azienda, con una registrazione accessibile per 60 giorni dopo la presentazione.
Beam Therapeutics (Nasdaq: BEAM) anunció que llevará a cabo una llamada de conferencia y una webcast el 5 de noviembre de 2024 a las 8:30 a.m. ET para discutir sus resultados financieros del tercer trimestre de 2024. La compañía también revisará los resúmenes aceptados para presentación en la 66ª Reunión Anual de la Sociedad Americana de Hematología (ASH). Un webcast en vivo estará disponible en el sitio web de la compañía, con una repetición accesible durante 60 días después de la presentación.
비임 테라퓨틱스 (Nasdaq: BEAM)은 2024년 11월 5일 오전 8시 30분 ET에 2024년 3분기 재무 결과에 대해 논의하기 위해 전화 회의 및 웹캐스트를 개최할 것이라고 발표했습니다. 회사는 또한 미국 혈액학회 (ASH) 제66회 연례 회의에서 발표될 초록들을 검토할 예정입니다. 회사 웹사이트에서 실시간 웹캐스트를 확인할 수 있으며, 발표 이후 60일 동안 다시 볼 수 있습니다.
Beam Therapeutics (Nasdaq: BEAM) a annoncé qu'elle tiendra une conférence téléphonique et un webinaire le 5 novembre 2024 à 8h30 ET pour discuter de ses résultats financiers du troisième trimestre 2024. L'entreprise examinera également les résumés acceptés pour présentation lors du 66ème Congrès Annuel de la Société Américaine d'Hématologie (ASH). Un webinaire en direct sera disponible sur le site de l'entreprise, avec une rediffusion accessible pendant 60 jours après la présentation.
Beam Therapeutics (Nasdaq: BEAM) gab bekannt, dass am 5. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast stattfinden wird, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen. Das Unternehmen wird auch die akzeptierten Abstracts zur Präsentation auf dem 66. Jahreskongress der American Society for Hematology (ASH) überprüfen. Ein Live-Webcast wird auf der Website des Unternehmens verfügbar sein, mit einer Wiederholung, die 60 Tage nach der Präsentation zugänglich ist.
- None.
- None.
CAMBRIDGE, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will host a conference call and webcast on Tuesday, November 5, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and review the company’s abstracts accepted for presentation at the upcoming 66th Annual Meeting of the American Society for Hematology (ASH).
A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the company’s website for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When will Beam Therapeutics (BEAM) report Q3 2024 earnings?
Where can I watch Beam Therapeutics (BEAM) Q3 2024 earnings webcast?
How long will Beam Therapeutics (BEAM) Q3 2024 earnings webcast be available for replay?
